

ODJFS P&T Committee Meeting Minutes

Wednesday, January 11, 2012

Riffe Building Room 1960, 77 S. High St., Columbus, OH 43215

Committee members present: Susan Baker, APN; Suzanne Eastman, RPh; Michael Howcroft, RPh; Cheryl Huffman, MD; Robert Hunter, DO (chair); Karen Jacobs, DO; Margaret Scott, RPh; Michael Wascovich, RPh; Mary Jo Welker, MD

ACS staff present: Stephanie Levine, RPh, Clinical Manager

Approximately 50 stakeholders were present, most representing pharmaceutical manufacturers and advocacy associations.

1) Conflict of Interest Policy

P&T Committee members signed agreement; a copy of the agreement is attached.

2) Interested party presentations

No requests for presentations were received.

3) Old Business

Dr. Jacobs and Dr. Huffman spoke about their experiences with the change of the pharmacy benefit to the managed care plans on October 1, 2011.

4) New Business:

Ms. Scott announced that ODJFS will release a request for proposals (RFP) for preferred diabetic supplies. The selection of preferred products will be based on both clinical considerations and net cost after rebates. Ms. Scott asked if the P&T Committee members want to be part of the clinical review of the products. The committee unanimously voted to review these products. Ms. Scott will work with the ODJFS Office of Legal and Acquisition Services to release the RFP in time for department staff to pre-screen the proposals and choose several potential products to be presented at the next P&T Committee meeting.

Drugs under consideration

a) Preferred Drug List New Drugs

i) Analgesics – Long-Acting Opioids: Nucynta ER CII (tapentadol extended-release) tablets, Janssen

A local physician presented information about Nucynta ER. The state and ACS recommend non-preferred status for the drug. The Committee voted 7-1 for preferred status, with the dissenting vote from ODJFS staff.

ii) Injectable Anti-Rheumatic Drugs: Orencia (abatacept) for subcutaneous administration, Bristol-Myers Squibb

A representative of Bristol-Myers Squibb presented information on Orencia. The state and ACS recommend non-preferred status for the drug. The committee unanimously agreed with the recommendation.

b) Other New Drugs

- i) Horizant (gabapentin enacarbil) extended-release tablets, GlaxoSmithKline
A representative from GlaxoSmithKline presented information on Horizant. The state and ACS recommend that the drug require prior authorization. The committee unanimously agreed with the recommendation.
- ii) Gralise (gabapentin) once-daily tablets, Depomed
A representative from Depomed and a local physician presented information on Gralise. The state and ACS recommend that the drug require prior authorization. The committee unanimously agreed with the recommendation.
- iii) Xarelto (rivaroxaban) tablets, 15mg and 20mg, Janssen
A representative from Janssen presented information on Xarelto 15mg and 20mg. The state and ACS recommend that the drug require prior authorization, with criteria the same as Pradaxa. The committee unanimously agreed with the recommendation.

The P&T Committee will meet the second Wednesday of January, April, and October, and the last Wednesday in June. Upcoming meetings are scheduled for:

April 11, 2012

June 27, 2012

October 10, 2012

January 9, 2013

Following the meeting, ODJFS determined that committee recommendations on Orencia, Horizant, Gralise, and Xarelto 15mg and 20mg will be implemented by February 15, 2012. The department is reviewing the recommendation for Nucynta ER.

**Ohio Department of Job and Family Services
Office of Ohio Health Plans**

**Pharmacy and Therapeutics Committee
Conflict of Interest Policy**

Purpose: To require members of the ODJFS Pharmacy and Therapeutics Committee to abide by this policy so that scientific and economic data serves as the primary basis in rendering objective decisions about drugs being considered for coverage by Ohio Health Plans.

Definition: A potential “conflict of interest” may exist when a committee member has a relationship with a manufacturer of the medication or class of medications being considered that could inappropriately influence his/her judgment, or the judgment of other members. This may include a relationship with a manufacturer of a drug which competes with the drug under consideration. A relationship with a manufacturer may include any of the following:

- Acceptance of honoraria
- Participation in speaker’s bureau
- Acceptance of support for travel for professional or education activities
- Acceptance of research support
- Relationship valued at \$500 or more with one company
- Consultant arrangement

Policy Statements

1. A member shall not participate in the discussion of an issue that is before the committee unless he/she has first disclosed any potentially relevant conflict of interest.
2. The committee will determine if a specific activity or relationship represents a potential conflict of interest and whether the member disclosing a potentially relevant conflict should continue to participate in the discussion.

Procedure: Committee members must sign this agreement once each year.

Signature _____ Date _____

Printed Name _____